These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 33605791

  • 1. Dutasteride Improves Nocturia but Does Not Lead to Better Sleep: Results from the REDUCE Clinical Trial.
    Kuhlmann PK, Fischer SC, Howard LE, Moreira DM, Andriole GL, Hopp ML, Roehrborn CG, Bliwise DL, Freedland SJ.
    J Urol; 2021 Jun; 205(6):1733-1739. PubMed ID: 33605791
    [Abstract] [Full Text] [Related]

  • 2. Impact of dutasteride on nocturia in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): a pooled analysis of three phase III studies.
    Oelke M, Roehrborn CG, D'Ancona C, Wilson TH, Castro R, Manyak M.
    World J Urol; 2014 Oct; 32(5):1141-7. PubMed ID: 24903347
    [Abstract] [Full Text] [Related]

  • 3. Nocturia improvement in the combination of Avodart(®) and tamsulosin (CombAT) study.
    Oelke M, Roehrborn CG, D'Ancona C, Wilson TH, Castro R, Manyak M.
    World J Urol; 2014 Oct; 32(5):1133-40. PubMed ID: 24804842
    [Abstract] [Full Text] [Related]

  • 4. Modeling study of the effect of placebo and medical therapy on storage and voiding symptoms, nocturia, and quality of life in men with prostate enlargement at risk for progression.
    Gravas S, Manuel-Palacios J, Chavan C, Roehrborn CG, Oelke M, Averbeck MA, Biswas A, García LM, Mohamed K, Cortes V.
    Prostate Cancer Prostatic Dis; 2024 Sep; 27(3):469-477. PubMed ID: 37794168
    [Abstract] [Full Text] [Related]

  • 5. Early effect of dutasteride added to alpha-1 blocker therapy for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Araki K, Naya Y, Inahara M, Suzuki F, Ota S, Tsuji H, Mikami K, Yanagisawa M, Awa Y, Suzuki H.
    Int J Urol; 2014 Aug; 21(8):815-9. PubMed ID: 24735081
    [Abstract] [Full Text] [Related]

  • 6. Sleep Problems are Associated with Development and Progression of Lower Urinary Tract Symptoms: Results from REDUCE.
    Branche BL, Howard LE, Moreira DM, Roehrborn C, Castro-Santamaria R, Andriole GL, Hopp ML, Freedland SJ.
    J Urol; 2018 Feb; 199(2):536-542. PubMed ID: 28870861
    [Abstract] [Full Text] [Related]

  • 7. Does Peak Urine Flow Rate Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from REDUCE.
    Simon RM, Howard LE, Moreira DM, Roehrborn C, Vidal A, Castro-Santamaria R, Freedland SJ.
    J Urol; 2017 Sep; 198(3):650-656. PubMed ID: 28428110
    [Abstract] [Full Text] [Related]

  • 8. Desmopressin add-on therapy for refractory nocturia in men receiving α-blockers for lower urinary tract symptoms.
    Bae WJ, Bae JH, Kim SW, Chung BH, Kim JH, Kim CS, Lee HM, Lee KS, Yoo TK, Kim SI, Byun SS, Lee JY.
    J Urol; 2013 Jul; 190(1):180-6. PubMed ID: 23357213
    [Abstract] [Full Text] [Related]

  • 9. Can we use baseline characteristics to assess which men with moderately symptomatic benign prostatic hyperplasia at risk of progression will benefit from treatment? A post hoc analysis of data from the 2-year CONDUCT study.
    Roehrborn CG, Oyarzabal Perez I, Roos EP, Calomfirescu N, Brotherton B, Palacios JM, Vasylyev A, Manyak MJ.
    World J Urol; 2017 Mar; 35(3):421-427. PubMed ID: 27334136
    [Abstract] [Full Text] [Related]

  • 10. Does Prostate Size Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from the REDUCE Trial.
    Simon RM, Howard LE, Moreira DM, Roehrborn C, Vidal AC, Castro-Santamaria R, Freedland SJ.
    Eur Urol; 2016 May; 69(5):885-91. PubMed ID: 26724841
    [Abstract] [Full Text] [Related]

  • 11. The Risk of Sexual Dysfunction and Effectiveness of Treatment of Benign Prostatic Hyperplasia With Severe Lower Urinary Tract Dysfunction With Combination of Dutasteride and Solifenacin.
    Kosilov K, Kuzina I, Kuznetsov V, Gainullina Y, Kosilova L, Karashchuk E, Prokofyeva A, Loparev S.
    J Sex Med; 2018 Nov; 15(11):1579-1590. PubMed ID: 30415813
    [Abstract] [Full Text] [Related]

  • 12. Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
    Roehrborn CG, Nickel JC, Andriole GL, Gagnier RP, Black L, Wilson TH, Rittmaster RS.
    Urology; 2011 Sep; 78(3):641-6. PubMed ID: 21764428
    [Abstract] [Full Text] [Related]

  • 13. Dutasteride improves bone mineral density in male patients with lower urinary tract symptoms and prostatic enlargement: a preliminary study.
    Wada N, Hashizume K, Matsumoto S, Kakizaki H.
    Aging Male; 2016 Sep; 19(1):12-4. PubMed ID: 26225793
    [Abstract] [Full Text] [Related]

  • 14. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor.
    O'Leary MP, Roehrborn C, Andriole G, Nickel C, Boyle P, Höfner K.
    BJU Int; 2003 Aug; 92(3):262-6. PubMed ID: 12887480
    [Abstract] [Full Text] [Related]

  • 15. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG, Barkin J, Tubaro A, Emberton M, Wilson TH, Brotherton BJ, Castro R.
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [Abstract] [Full Text] [Related]

  • 16. Effects of Withdrawing α1-Blocker from Combination Therapy with α1-Blocker and 5α-Reductase Inhibitor in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: A Prospective and Comparative Trial Using Urodynamics.
    Matsukawa Y, Takai S, Funahashi Y, Majima T, Kato M, Yamamoto T, Gotoh M.
    J Urol; 2017 Oct; 198(4):905-912. PubMed ID: 28499730
    [Abstract] [Full Text] [Related]

  • 17. [Efficacy of 5-reductase inhibitors in the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia].
    Nizov AN.
    Urologiia; 2019 Dec; (5):156-160. PubMed ID: 31808653
    [Abstract] [Full Text] [Related]

  • 18. Intravesical Prostatic Protrusion as a Predicting Factor for the Adverse Clinical Outcome in Patients With Symptomatic Benign Prostatic Enlargement Treated With Dutasteride.
    Yoshida T, Kinoshita H, Yoshida K, Mishima T, Taniguchi H, Yanishi M, Komai Y, Yasuda K, Sugi M, Matsuda T.
    Urology; 2016 May; 91():154-7. PubMed ID: 26826590
    [Abstract] [Full Text] [Related]

  • 19. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
    Roehrborn CG, Barkin J, Siami P, Tubaro A, Wilson TH, Morrill BB, Gagnier RP.
    BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
    [Abstract] [Full Text] [Related]

  • 20. Serum cholesterol and risk of lower urinary tract symptoms progression: Results from the Reduction by Dutasteride of Prostate Cancer Events study.
    Feng T, Howard LE, Vidal AC, Moreira DM, Castro-Santamaria R, Andriole GL, Freedland SJ.
    Int J Urol; 2017 Feb; 24(2):151-156. PubMed ID: 28004415
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.